2BB score and signals
Madrigal Pharmaceuticals, Inc.’s current 2BB score is 59 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 71 | High |
| Momentum | 54 | Stable |
| Financial strength | 37 | Weak |
| Quality | 97 | Very Strong |
| Risk | 28 | Low |
Company facts
| CEO | Paul A. Friedman |
| Headquarters | West Conshohocken, Pennsylvania, United States |
| Founded | 2011 |
| Employees | 915 |
| 52-week range | $393.60 – $614.36 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-17 | — | -0.266 | — | $453.43M |
| 2026-10-29 | — | -0.9007 | — | $412.94M |
| 2026-07-30 | — | -2.6639 | — | $357.14M |
| 2026-05-06 | -3.25 | -4.1098 | $311.34M | $306.78M |
Related companies
